The slow development of major advances in drug discovery for the treatment of Mycobacterium tuberculosis (Mtb) infection have led to a compelling need for evaluation of more effective drug therapies against tuberculosis. New classes of drugs are constantly being evaluated for anti-mycobacterial activity with currently a very limited number of new drugs approved for TB treatment. Minor Groove Binders (MGBs) have previously revealed promising anti-microbial activity against various infectious agents; however have not yet been screened against Mtb.
|Number of pages||8|
|Journal||Journal of Antimicrobial Chemotherapy|
|Early online date||18 Sept 2017|
|Publication status||Published - 1 Dec 2017|
- drug discovery
- minor groove binder
FingerprintDive into the research topics of 'Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents, and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy'. Together they form a unique fingerprint.
- Strathclyde Institute Of Pharmacy And Biomedical Sciences - Senior Lecturer
- Pure And Applied Chemistry - Senior Lecturer